JB Chemicals & Pharmaceuticals on Saturday announced its financial results for the second quarter that ended 30th September, 2022. For the second quarter ended 30th September 2022, the Company recorded revenue of Rs 809 crores as compared to Rs 593 crores recorded in the same quarter last year, registering growth of 36 per cent.
Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 44 per cent quarter on quarter to Rs 202 crores as compared to Rs 140 crores registered in the corresponding quarter in the previous year.
The company's net profits for the quarter two of the financial year 2023 (Q2FY23) stood at Rs 111 crores as compared to Rs 98 crores posted in Q2FY22, registering a growth of 13 per cent.
The pharma company in a statement said that its domestic formulations business maintained its market-beating performance growing at 45 per cent in Q2 FY23, and the international business also continued its strong momentum growing at 28 per cent to Rs 375 crores in Q2 FY23
Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma said, “We continue to build further on our strong operating performance across business segments in FY 23. Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period.